IPO ROUND-UP: Invuity and Endochoice lower the bar, but IPO hopefuls keep coming
This article was originally published in Clinica
Lowering one’s expectations is becoming the unfortunate norm when it comes to medtech IPOs. Since last month, Clinica has added two more downsized public market debuts, which means of the 13 completed IPOs recorded for the year to date, nine raised less money than they had initially hoped (see Table 1). The two new additions to Clinica’s IPO tracker are Invuity and EndoChoice, both in the field of minimally invasive surgery.
You may also be interested in...
Boston Scientific is making a significant investment in its endoscopy portfolio as it strikes a $210m deal to buy colonoscopy specialist EndoChoice. The Natick, Massachusetts, group added that it will be “evaluating strategic options” for EndoChoice’s Fuse colonoscope.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.